NCT05063656View on ClinicalTrials.gov

Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Autism Spectrum Disorder

Interventions

DRUG

Gabapentin

8 weeks of gabapentin, titrated up to 20 mg/kg in 3 divided doses daily

Trial Locations (1)

01655

RECRUITING

University of Massachusetts Medical School, Worcester

All Listed Sponsors

collaborator

Eagles Autism Foundation

UNKNOWN

lead

David Cochran

OTHER

NCT05063656 - Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin | Biotech Hunter | Biotech Hunter